Tumor Enhancement on Dynamic CT: A Predictive Factor for Recurrence After Nephrectomy in Localized T1 Clear Cell Renal Cell Carcinoma.

PMID- 29599364
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Tumor Enhancement on Dynamic CT: A Predictive Factor for Recurrence After
      Nephrectomy in Localized T1 Clear Cell Renal Cell Carcinoma.
PG  - 2377-2383
AB  - AIM: To investigate whether radiological parameters obtained on dynamic computed 
      tomography (CT), especially those related to tumor enhancement, are predictive
      factors for recurrence after nephrectomy in localized stage T1 clear cell renal
      cell carcinoma (ccRCC). MATERIALS AND METHODS: We retrospectively studied 88
      patients with localized stage T1 ccRCC who underwent dynamic CT preoperatively.
      Seven patients had recurrent disease after surgery. Tumor attenuations were
      measured by placing a region of interest in the solid region. TApre and TAneph
      were defined as the tumor attenuation values of the pre-contrast and
      nephrographic phase, respectively. The correlations between disease-free survival
      and clinicopathological factors, including the radiological parameter TAneph -
      TApre (DeltaTAneph), were analyzed by Cox proportional hazards model or
      Kaplan-Meier method with the log-rank test. RESULTS: Only DeltaTAneph was
      significantly and positively correlated with disease-free survival (p<0.05).
      Tumor size also tended to be negatively correlated with disease-free survival
      (p<0.1). The 5- and 10-year disease-free survival rates of the group with high
      DeltaTAneph (>/=86 HU) were 97.4% and 97.4%, while those of the group with low
      DeltaTAneph (<86 HU) were 89.6% and 71.6%, respectively. CONCLUSION: Tumor
      enhancement in the nephrographic phase of CT was a predictive factor for
      recurrence after nephrectomy in patients with localized stage T1 ccRCC.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Maehara, Junki
AU  - Maehara J
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Nishie, Akihiro
AU  - Nishie A
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan [email protected]
FAU - Asayama, Yoshiki
AU  - Asayama Y
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Ishigami, Kousei
AU  - Ishigami K
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Ushijima, Yasuhiro
AU  - Ushijima Y
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Takayama, Yukihisa
AU  - Takayama Y
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Okamoto, Daisuke
AU  - Okamoto D
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Fujita, Nobuhiro
AU  - Fujita N
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Sugimoto, Masaaki
AU  - Sugimoto M
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Inokuchi, Junichi
AU  - Inokuchi J
AD  - Department of Urology, Graduate School of Medical Sciences, Kyushu University,
      Fukuoka, Japan.
FAU - Honda, Hiroshi
AU  - Honda H
AD  - Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Renal Cell/*diagnosis/pathology/*surgery
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*diagnosis/pathology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*diagnosis
MH  - Nephrectomy
MH  - Predictive Value of Tests
MH  - Radiographic Image Enhancement/*methods
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed/*methods
OTO - NOTNLM
OT  - *CT
OT  - *RCC
OT  - *clear cell
OT  - *recurrence
OT  - *tumor enhancement
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/01/12 00:00 [received]
PHST- 2018/02/12 00:00 [revised]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2377 [pii]
AID - 10.21873/anticanres.12486 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2377-2383. doi: 10.21873/anticanres.12486.